WPD103

DEVELOPMENT OF A NEW MEDICINE USED IN THE DIAGNOSTIC AND TREATMENT OF CANCER 

OVERVIEW

WPD103 is a radiopharmaceutical based on the expression of tumor specific receptors, such as IL-13RA2 and EphA2, which are not detected in normal cells, which express mainly IL-13RA1 and Eph-RA1 proteins. The breakthrough of WPD Pharmaceuticals’ solution is expected to be a new diagnostic tool and targeted therapy against IL-13RA2 and EphA2 receptors by genetically modified IL-13 and Ephrin 1 cytokines, conjugated to radionuclides. Recombinant cytokines preferentially bound to tumor-specific receptors will allow for highly specific targeting of cancer cells and their further elimination due to  radiation induced cytotoxic effects. The Project's result should allow patients access to an innovative molecular diagnostic tool and, later, targeted therapies as an alternative to conventional treatment. The solution falls within the scope of theranostics, a novel approach combining diagnostics with cancer therapy.

CLINICAL DEVELOPMENT

WPD103 is currently in preclinical development and based on the data obtained from in vitro studies using cancer cell lines and WPD101 in spontaneous GBM dog model studies, we see significant potential for WPD103 in diagnostics and therapy in humans.  Phase I clinical trial is expected to begin in 2022-23.

 

GRANTS / FUNDING

  • In July 2018, WPD started developing a scientific program and grant proposal for submission in 2019/2020

REGULATORY

  • WPD103 has not been submitted for FDA or EMA approval so far

PARTNERS, AFFILIATIONS & LICENSE

  • Wake Forest Baptist Medical Center is a recognized, fully integrated academic medical center and health system located in Winston-Salem, North Carolina, USA
  • North Carolina Baptist Hospital operates inpatient hospitals, community health centers, health maintenance organization, primary care centers and teaching hospital as a subsidiary of Wake Forest Baptist Medical Center
  • Lower Silesian Center of Oncology in Wroclaw, Poland
  • WPD owns the exclusive global rights  

MARKET OPPORTUNITY

Withno other curative options available, we believe WPD103 may have the potential for an early approval and to become a highly effective and safe therapy for different types of tumors. 

The expected market size is in excess of $1 Billion. 

R & D